Law360, New York (October 12, 2003, 12:00 AM ET) -- A European patent appeals board invalidated a patent that Serono SA claimed had been infringed by Transkaryotic Therapies, Transkaryotic said in a statement.
Serono filed a lawsuit against Transkaryotic in the District Court at The Hague in the Netherlands in February, alleging that Transkaryotic infringed a gene-activation patent related to its drug Replagal for Fabry disease, a rare genetic disorder.
However, the Technical Board of Appeals of the European Patent Office invalidated the patent held by Serono's subsidiary, Applied Research Systems ARS Holdings, N.V., Transkaryotic said...
European Patent Appeals Board Rules for Transkaryotic
To view the full article, take a free trial now.
